Autres langues Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/05/2026			Varia. 5j.	Varia. 1 janv.
16,87 ^USD	-7,00 %		-1,63 %	-3,54 %

04/05	Synthèse de la recherche aux États-Unis - Alphabet, Colgate-Palmolive, Welltower	RE
30/04	Summit Therapeutics Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

04/05	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower
30/04	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q1 Adjusted Loss $0.15 per Share, vs. FactSet Est of $-0.17
30/04	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
30/04	Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
27/04	Acurx Pharmaceuticals, Inc., Adiso Therapeutics, Inc., Summit Therapeutics Inc., Finch Therapeutics Group, Inc. and Astrazeneca plc Announces Clostridium Difficile Infections Clinical Trial Updates
27/03	Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy
27/03	Health-Related Quality of Life With Ivonescimab Versus Pembrolizumab for PD-L1 Positive, Non–Small Cell Lung Cancer (HARMONi-2): A Randomised, Double-Blind, Phase 3 Study in China
27/03	Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026
27/03	Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
27/02	Summit Therapeutics to Present at Upcoming Investor Conferences
23/02	Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise
23/02	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q4 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.09
23/02	Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
23/02	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
17/02	Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
09/02	Avacta appoints new chief scientific officer, plans clinical trials
09/02	Avacta Therapeutics Announces Executive Changes
30/01	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
29/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
29/01	Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab
29/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
13/01	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says
12/01	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
12/01	Summit Therapeutics, GSK Team up on Clinical Trial for Combination Cancer Therapy